Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT

F L Delarue1, J Adnane, B Joshi

  • 1Drug Discovery Program at H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Oncogene
|August 16, 2006
PubMed

Insights

Novel anticancer agents, farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase I inhibitors (GGTIs), upregulate RhoB expression in various human cancers. This occurs via transcriptional regulation and promoter acetylation, offering a new therapeutic mechanism.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • RhoB protein plays a crucial role in suppressing malignant transformation and metastasis.
  • EGFR, ErbB2, Ras, and Akt signaling pathways are implicated in cancer progression.

Purpose of the Study:

  • To investigate the effect of farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase I inhibitors (GGTIs) on RhoB expression in human cancer cells.
  • To elucidate the regulatory mechanism of RhoB induction by FTIs and GGTIs.

Main Methods:

  • Treatment of various human cancer cell lines (pancreatic, breast, lung, colon, bladder, brain) with FTIs (e.g., FTI-277) and GGTIs (e.g., GGTI-298).
  • Analysis of RhoB expression levels using Western blotting and reverse transcription-PCR.
  • Assessment of transcriptional regulation using actinomycin D.
  • Chromatin immunoprecipitation assays to study histone modifications (acetylation) and protein interactions (HDAC1, HAT) at the RhoB promoter.

Main Results:

  • FTIs and GGTIs significantly upregulate RhoB expression across a wide spectrum of human cancer cells.
  • RhoB induction is mediated at the transcriptional level, as evidenced by increased RhoB transcription and blockage by actinomycin D.
  • Anticancer agent treatment leads to dissociation of HDAC1, association of HAT, and histone acetylation of the RhoB promoter.

Conclusions:

  • FTIs and GGTIs represent novel therapeutic agents that can upregulate RhoB expression in cancer cells.
  • RhoB promoter acetylation is identified as a novel mechanism regulating RhoB expression in response to FTIs and GGTIs.
  • Targeting RhoB expression through promoter acetylation may offer a new strategy for cancer therapy.

Related Concept Videos

Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
RNA Polymerase II Accessory Proteins02:36

RNA Polymerase II Accessory Proteins

Proteins that regulate transcription can do so either via direct contact with RNA Polymerase or through indirect interactions facilitated by adaptors, mediators, histone-modifying proteins, and nucleosome remodelers. Direct interactions to activate transcription is seen in bacteria as well as in some eukaryotic genes. In these cases, upstream activation sequences are adjacent to the promoters, and the activator proteins interact directly with the transcriptional machinery. For example, in...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...